Methamphetamine exposure during the preweanling period causes prolonged changes in dorsal striatal protein kinase A activity, dopamine D2-like binding sites, and dopamine content

Synapse

Volumn 48, Issue 3, 2003, Pages 131-137

  Crawford, Cynthia A ^a   Williams, Michael T ^b   Newman, Eva R ^a   McDougall, Sanders A ^a   Vorhees, Charles V ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

D methamphetamine; Dopamine D2 like receptors; Ontogeny; Protein kinase A

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AMPHETAMINE DERIVATIVE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE; DOPAMINE 2 RECEPTOR; METHAMPHETAMINE; SPIPERONE; TRITIUM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; ENZYME ASSAY; FEMALE; LEARNING; LOCOMOTION; NEUROTOXICITY; NEWBORN; NONHUMAN; ONTOGENY; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PUTAMEN; RAT; STARTLE REFLEX; WEANING;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANIMALS, NEWBORN; BINDING SITES; BINDING, COMPETITIVE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOPAMINE; FEMALE; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEX CHARACTERISTICS; TIME FACTORS;

EID: 0344950507     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10197     Document Type: Article

References (56)

1. Abel T, Nguyen PV, Barad M, Deuel TA, Kandel ER, Bourtchouladze R. 1997. Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. Cell 88:615-626.
2. Bale TL, Davis AM, Auger AP, Dorsa DM, McCarthy MM. 2001. CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. J Neurosci 21:2546-2552.
3. Banu SK, Govindarajulu P, Aruldhas MM. 2002. Developmental profiles of TSH, sex steroids, and their receptors in the thyroid and their relevance to thyroid growth in immature rats. Steroids 67: 137-144.
4. Barnett JV, Segal DS, Kuczenski R. 1987. Repeated amphetamine pretreatment alters the responsiveness of striatal dopamine-stimulated adenylate cyclase to amphetamine-induced desensitization. J Pharmacol Exp Ther 242:40-47.
5. Bowyer JF, Tank AW, Newport GD, Slikker W, Ali SF, Holson RR. 1992. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260:817-824.
6. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Cappon GD, Morford LL, Vorhees CV. 1997. Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response. Dev Brain Res 103:155-162.
8. Cappon GD, Pu C, Vorhees CV. 2000. Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment. Brain Res 863:106-111.
9. Chapman DE, Hanson GR, Kesner RP, Keefe KA. 2001. Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J Pharmacol Exp Ther 296:520-527.
10. Crawford CA, Zavala AR, Karper PE, Collins RL, Meier TL, Watson JB, McDougall SA. 2000a. Amphetamine treatment during the preweanling period produces long-term changes in striatal protein kinase A activity. Pharmacol Biochem Behav 66:835-840.
11. 2-like binding sites, and dopamine content. Neurotoxicol Teratol 22:799-804.
12. Davidson C, Gow AJ, Lee TH, Ellinwood EH. 2001. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 36:1-22.
13. Dluzen DE. 2000. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J Neurocytol 29:387-399.
14. Dluzen DE, McDermott JL. 2000. Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system. Ann NY Acad Sci 914:112-126.
15. Eisch AJ, Gaffney M, Weihmuller FB, O'Dell SJ, Marshall JF. 1992. Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res 598:321-326.
16. Fornai F, Battaglia G, Gesi M, Orzi F, Nicoletti F, Ruggieri S. 2001. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res 898:27-35.
17. Fukumura M, Cappon GD, Broening HW, Vorhees CV. 1998. Methamphetamine-induced dopamine and serotonin reductions in neostriatum are not gehder specific in rats with comparable hyperthermic responses. Neurotoxicol Teratol 20:441-448.
18. Gao X, Dluzen DE. 2001. The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res 893:63-69.
19. Hughes CW. 1979. Outcome of early experience studies as affected by between-litters variance. J Nutr 109:642-645.
20. Joseph A, Kumar A, O'Connell NA, Agarward RK, Gwosdow AR. 1995. Interleukin-1 alpha stimulates dopamine release by activating type II protein kinase A in PC-12 cells. Am J Physiol 269:1083-1088.
21. Kebabian JW, Calne BB. 1979. Multiple receptors for dopamine. Nature 277:93-96.
22. Kokoshka JM, Fleckenstein AE, Wilkins DG, Hanson GR. 2000. Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine. J Neurochem 75:2095-2102.
23. 1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J Pharmacol Exp Ther 286:345-353.
24. Lucot JB, Wagner GC, Schuster CR, Seiden LS. 1982. Decreased sensitivity of rat pups to long-lasting dopamine and serotonin depletions produced by methylamphetamine. Brain Res 247:181-183.
25. 2 dopamine receptors as evidenced by autoradiography: comparison with tyrosine hydroxylase activity. Neuroscience 23:253-261.
26. Micheau J, Riedel G. 1999. Protein kinases: which one is the memory molecule? Cell Mol Life Sci 55:534-548.
27. Miller DB, Ali SF, O'Callaghan JP, Laws SC. 1998. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci 844:153-165.
28. O'Callaghan JP, Miller DB. 2002. Neurotoxic effects of substituted amphetamines in rats and mice: challenges to the current dogma. In: Massaro EJ, editor. Handbook of neurotoxicity, vol. 2. Totowa, NJ: Humana Press. p 269-301.
29. 2 antagonists. J Neurochem 60:1792-1799.
30. Pu C, Vorhees CV. 1993. Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum. Dev Brain Res 72:325-328.
31. Ricaurte GA, Schuster CR, Seiden LS. 1980. Long-term effects on repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 193: 153-163.
32. Riddle EL, Kokoshka JM, Wilkins DG, Hanson GR, Fleckenstein AE. 2002. Tolerance to the neurotoxic effects of methamphetamine in young rats. Eur J Pharmacol 435:181-185.
33. Roberson ED, English JD, Adams JP, Selcher JC, Kondratick C, Sweatt JD. 1999. The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus. J Neurosci 19:4337-4348.
34. Roseboom RH, Hewlett GH, Gnegy ME. 1990. Repeated amphetamine administration alters the interaction between D1-stimulated adenylyl cyclase activity and calmodulin in rat striatum. J Pharmacol Exp Ther 255:197-203.
35. Sabol KE, Roach JT, Broom SL, Ferreira C, Preau MM. 2001. Long-term effects of a high-dose methamphetamine regimen on subsequent methamphetamine-induced dopamine release in vivo. Brain Res 892:122-129.
36. Schafe GE, LeDoux JE. 2000. Memory consolidation of auditory Pavlovian fear conditioning requires protein synthesis and protein kinase A in the amygdala. J Neurosci 20:1-5.
37. Shishido T; Watanabe Y, Suzuki H, Kato K, Niwa S-I, Hanoune J, Matsuoka I. 1997. Effects of repeated methamphetamine administration on dopamine D 1 receptor, D2 receptor and adenylate cyclase type V mRNA levels in the rat striatum. Neurosci Lett 222:175-178.
38. Sibley DR, Monsma FJ. 1992. Molecular biology of dopamine receptors. Trends Pharmacol Sci 68:97-106.
39. Terwilliger R, Beitner-Johnson D, Sevarino KA, Crain SM, Nestler EJ. 1991. A general role of adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res 548:100-110.
40. Tolliver BK, Ho LB, Fox LM, Berger SP. 1999. Necessary role for ventral tegmental area adenylate cyclase and protein kinase A in induction of behavioral sensitization to intraventral tegmental area amphetamine. J Pharmacol Exp Ther 289:38-47.
41. Vorhees CV, Pu C. 1995. Ontogeny of methamphetamine-induced neurotoxicity in the rat model. NIDA Res Monogr 158:149-171.
42. Vorhees CV, Ahrens KG, Acuff-Smith KD, Schilling MA, Fisher JE. 1994a. Methamphetamine exposure during early postnatal development in rats. I. Acoustic startle augmentation and spatial learning deficits. Psychopharmacology 114:392-401.
43. Vorhees CV, Ahrens KG, Acuff-Smith KD, Schilling MA, Fisher JE. 1994b. Methamphetamine exposure during early postnatal development in rats. II. Hypoactivity and altered responses to pharmacological challenge. Psychopharmacology 114:402-408.
44. Vorhees CV, Reed TM, Schilling MS, Acuff-Smith KD, Fisher JE, Moran MS. 1996. Neonatal methamphetamine-induced long-term acoustic startle facilitation in rats as a function of prepulse stimulus intensity. Neurotoxicol Teratol 18:135-139.
45. Vorhees CV, Reed TM, Schilling MA, Fisher JE, Moran MS, Cappon GD, Nebert DW. 1998. CYP2D1 polymorphism in methamphetamine-treated rats: genetic differences in neonatal mortality and effects on spatial learning and acoustic startle. Neurotoxicol Teratol 20:265-273.
46. Vorhees CV, Morford LL, Inman SL, Reed TM, Schilling MA, Cappon GD, Moran MS, Nebert DW. 1999. Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine. Pharmacogenetics 9:171-181.
47. Vorhees CV, Inman-Wood SL, Morford LL, Broening HW, Fukumura M, Moran MS. 2000. Adult learning deficits after neonatal exposure to D-methamphetamine: selective effects on spatial navigation and memory. J Neurosci 20:4732-4739.
48. Wagner GC, Ricaurte GA, Johanson CE, Schuster CR, Seiden LS. 1980a. Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate. Neurology 30:547-550.
49. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. 1980b. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181:151-160.
50. Wagner GC, Schuster CR, Seiden LS. 1981. Neurochemical consequences following administration of CNS stimulant to the neonatal rat. Pharmacol Biochem Behav 14:117-119.
51. Wagner GC, Tekirian TL, Cheo CT. 1993: Sexual differences in sensitivity to methamphetamine toxicity. J Neural Transm 93:67-70.
52. Walaas SI, Greengard P. 1991. Protein phosphorylation and neuronal function. Pharmacol Rev 43:299-349.
53. Wallace TL, Gudelsky GA, Vorhees CV. 2001. Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine. Psychopharmacology 153:321-326.
54. Williams MT, Vorhees CV, Boon F, Saber AJ, Cain DP. 2002. Methamphetamine exposure from postnatal day 11 to 20 causes impairments in both behavioral strategies and spatial learning in adult rats. Brain Res 958:312-321.
55. Yu L, Liao P-C. 2000. Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J Neural Transm 107:419-427.
56. Yu YL, Wagner GC. 1994. Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity. J Neural Transm Park Dis Dement Sect 8:215-221.